Patients newly diagnosed with prostate cancer who have a prostate specific antigen levels of 4.0 ng/mL or below tend to receive aggressive therapy despite having a low risk of disease, according to a retrospective study of 123,934 men in the July 26 issue of the Archives of Internal Medicine.In a multivariate analysis correcting for age, race, and year of diagnosis, men with screen-detected prostate cancer and prostate specific antigen (PSA) values of 4.0 ng/mL or below were 49% more likely to undergo...